Pfizer Inc. (NYSE:PFE) Stake Raised by Gilman Hill Asset Management LLC

Gilman Hill Asset Management LLC boosted its holdings in Pfizer Inc. (NYSE:PFEFree Report) by 6.9% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 258,938 shares of the biopharmaceutical company’s stock after acquiring an additional 16,604 shares during the quarter. Pfizer comprises about 1.3% of Gilman Hill Asset Management LLC’s investment portfolio, making the stock its 26th biggest holding. Gilman Hill Asset Management LLC’s holdings in Pfizer were worth $7,186,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. VisionPoint Advisory Group LLC raised its holdings in Pfizer by 52,350.0% during the 3rd quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock worth $35,000 after buying an additional 1,047 shares during the period. GoalVest Advisory LLC grew its stake in Pfizer by 304.9% during the 4th quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock valued at $31,000 after acquiring an additional 811 shares in the last quarter. Creekmur Asset Management LLC purchased a new position in Pfizer during the 4th quarter valued at about $32,000. Tennessee Valley Asset Management Partners purchased a new position in Pfizer during the 4th quarter valued at about $36,000. Finally, DiNuzzo Private Wealth Inc. purchased a new position in Pfizer during the 4th quarter valued at about $37,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Stock Down 1.0 %

Shares of NYSE:PFE traded down $0.28 during trading on Tuesday, hitting $28.08. 10,995,468 shares of the company were exchanged, compared to its average volume of 41,033,609. The stock has a market cap of $159.12 billion, a price-to-earnings ratio of -470.09, a P/E/G ratio of 1.09 and a beta of 0.70. Pfizer Inc. has a fifty-two week low of $25.20 and a fifty-two week high of $37.80. The firm has a fifty day moving average price of $27.72 and a two-hundred day moving average price of $27.70. The company has a current ratio of 1.05, a quick ratio of 0.78 and a debt-to-equity ratio of 0.66.

Pfizer (NYSE:PFEGet Free Report) last posted its earnings results on Wednesday, May 1st. The biopharmaceutical company reported $0.82 earnings per share for the quarter, topping analysts’ consensus estimates of $0.56 by $0.26. Pfizer had a positive return on equity of 8.64% and a negative net margin of 0.56%. The business had revenue of $14.88 billion for the quarter, compared to analyst estimates of $13.87 billion. During the same period in the previous year, the firm earned $1.23 EPS. The firm’s revenue was down 19.5% compared to the same quarter last year. As a group, research analysts anticipate that Pfizer Inc. will post 2.37 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, June 14th. Stockholders of record on Friday, May 10th were given a dividend of $0.42 per share. The ex-dividend date of this dividend was Thursday, May 9th. This represents a $1.68 dividend on an annualized basis and a dividend yield of 5.98%. Pfizer’s payout ratio is -2,799.53%.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on PFE shares. BMO Capital Markets reaffirmed an “outperform” rating and set a $36.00 target price (up previously from $33.00) on shares of Pfizer in a research note on Thursday, May 2nd. Morgan Stanley boosted their price target on Pfizer from $28.00 to $29.00 and gave the company an “equal weight” rating in a research note on Thursday, May 2nd. Argus cut Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $45.00 price target on shares of Pfizer in a research note on Monday, June 17th. Ten research analysts have rated the stock with a hold rating and six have given a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $35.86.

Get Our Latest Stock Report on PFE

Pfizer Profile

(Free Report)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Featured Articles

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.